[EN] COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS ET MÉTHODES POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
申请人:UNIV WASHINGTON
公开号:WO2011050323A1
公开(公告)日:2011-04-28
The present invention encompasses compounds and methods for treating urinary tract infections.
本发明包括用于治疗尿路感染的化合物和方法。
COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS
申请人:Janetka James W.
公开号:US20120309701A1
公开(公告)日:2012-12-06
The present invention encompasses compounds and methods for treating urinary tract infections.
本发明涵盖了治疗尿路感染的化合物和方法。
Compounds and methods for treating bacterial infections
申请人:Janetka James W.
公开号:US08937167B2
公开(公告)日:2015-01-20
The present invention encompasses compounds and methods for treating urinary tract infections.
本发明涵盖了用于治疗尿路感染的化合物和方法。
Lead Optimization Studies on FimH Antagonists: Discovery of Potent and Orally Bioavailable Ortho-Substituted Biphenyl Mannosides
作者:Zhenfu Han、Jerome S. Pinkner、Bradley Ford、Erik Chorell、Jan M. Crowley、Corinne K. Cusumano、Scott Campbell、Jeffrey P. Henderson、Scott J. Hultgren、James W. Janetka
DOI:10.1021/jm300165m
日期:2012.4.26
Herein, we describe the X-ray structure-based design and optimization of biaryl mannoside FimH inhibitors. Diverse modifications to the biaryl ring to improve druglike physical and pharmacokinetic properties of mannosides were assessed for FimH binding affinity based on their effects on hemagglutination and biofilm formation along with direct FimH binding assays. Substitution on the mannoside phenyl ring ortho to the glycosidic bond results in large potency enhancements several-fold higher than those of corresponding unsubstituted matched pairs and can be rationalized from increased hydrophobic interactions with the FimH hydrophobic ridge (Ile13) or "tyrosine gate" (Tyr137 and Tyr48) also lined by Ile52. The lead mannosides have increased metabolic stability and oral bioavailability as determined from in vitro PAMPA predictive model of cellular permeability and in vivo pharmacokinetic studies in mice, thereby representing advanced preclinical candidates with promising potential as novel therapeutics for the clinical treatment and prevention of recurring urinary tract infections.